Systemic corticosteroid treatment in Vogt-Koyanagi-Harada disease
- PMID: 7056483
- DOI: 10.1007/BF02134092
Systemic corticosteroid treatment in Vogt-Koyanagi-Harada disease
Abstract
Twenty patients with Vogt-Koyanagi-Harada disease who had been given systemic corticosteroids were retrospectively analyzed. Sixteen patients were successfully treated with systemic corticosteroids without recurrence of uveitis. Since the advent of corticosteroid treatment, there have been fewer ocular complications as well as extraocular sings and symptoms in most cases. Recurrence of the inflammation, however, occurred in four cases. Drip infusion of 200 mg prednisolone daily, widely employed for the treatment, did not always have good results. It is suggested that the dosage of corticosteroid should be adjusted according to the severity of uveomeningitis. Oral administration of corticosteroid (less than 100 mg prednisolone daily) may be enough for suppression of the inflammation in the Harada type, while a drip infusion of the massive dosage (more than 200 mg prednisolone daily) with gradual tapering off is possible requisite in the Vogt-Koyanagi type.
Similar articles
-
Studies on corticosteroid therapy in Vogt-Koyanagi-Harada disease.Ophthalmologica. 1990;201(3):162-7. doi: 10.1159/000310145. Ophthalmologica. 1990. PMID: 2089358
-
Vogt-Koyanagi-Harada syndrome.Am J Ophthalmol. 1977 May;83(5):735-40. doi: 10.1016/0002-9394(77)90142-8. Am J Ophthalmol. 1977. PMID: 868972
-
Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.Acta Ophthalmol. 2017 Feb;95(1):85-90. doi: 10.1111/aos.13189. Epub 2016 Aug 18. Acta Ophthalmol. 2017. PMID: 27535102
-
Vogt-Koyanagi-Harada disease.Surv Ophthalmol. 2017 Jan-Feb;62(1):1-25. doi: 10.1016/j.survophthal.2016.05.002. Epub 2016 May 27. Surv Ophthalmol. 2017. PMID: 27241814 Review.
-
Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease.Int Ophthalmol. 2019 Jun;39(6):1419-1425. doi: 10.1007/s10792-018-0949-4. Epub 2018 Jun 11. Int Ophthalmol. 2019. PMID: 29948499 Review.
Cited by
-
Prognostic factors in Vogt-Koyanagi-Harada disease.Int Ophthalmol. 2007 Apr-Jun;27(2-3):201-10. doi: 10.1007/s10792-007-9062-9. Epub 2007 Apr 14. Int Ophthalmol. 2007. PMID: 17435968
-
Comparative study of efficacy and safety of pulse versus half-pulse steroid therapy for Vogt-Koyanagi-Harada Disease.Jpn J Ophthalmol. 2025 Sep;69(5):805-812. doi: 10.1007/s10384-025-01213-3. Epub 2025 May 26. Jpn J Ophthalmol. 2025. PMID: 40418489 Free PMC article.
-
Significant prognostic factors for Vogt-Koyanagi-Harada disease in the early stage.Kaohsiung J Med Sci. 2004 Mar;20(3):97-105. doi: 10.1016/S1607-551X(09)70092-0. Kaohsiung J Med Sci. 2004. PMID: 15124893 Free PMC article.
-
Almost simultaneous onset of Vogt-Koyanagi-Harada syndrome in co-workers, friends, and neighbors.Graefes Arch Clin Exp Ophthalmol. 2004 Jul;242(7):611-3. doi: 10.1007/s00417-004-0888-9. Epub 2004 Feb 17. Graefes Arch Clin Exp Ophthalmol. 2004. PMID: 14986015
-
Vogt-Koyanagi-Harada disease in Hispanic patients.Int Ophthalmol. 2007 Apr-Jun;27(2-3):143-8. doi: 10.1007/s10792-006-9017-6. Epub 2007 Mar 23. Int Ophthalmol. 2007. PMID: 17380271
References
MeSH terms
Substances
LinkOut - more resources
Medical